Antimicrobial Resistance Clinical Trial
Official title:
Surveillance of Healthcare-associated Infections & Antimicrobial Resistance
The aims of this project, called "Surveillance of Healthcare-associated infections & Antimicrobial Resistance", or "SHARE", are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats
The World Health Organization (WHO) has declared antimicrobial resistance (AMR) one of the top 10 global public health threats facing humanity. AMR burden is higher in low-and-middle-income countries (LMICs) where, in recent decades, incidence and mortality from healthcare-associated infections (HAI) due to multidrug resistant organisms (MDRO) have dramatically increased. For example, neonatal sepsis is the third most common cause of neonatal deaths and multidrug-resistant Gram-negative bacteria are now the leading cause of sepsis among hospitalized neonates in south Asia and sub-Saharan Africa, including Botswana.1,2 One in three newborns with an MDRO bloodstream infection will die.3 In 2021, to respond to the global threat of AMR, U.S. Centers for Disease Control & Prevention (CDC) announced the launch of a global "network of networks" to tackle the problem of AMR and healthcare-associated infections (HAIs). The network, called "Global Antimicrobial Resistance Laboratory and Response Network", solicited funding applications; in December of 2021, Botswana was announced as recipient of a 5-year cooperative agreement following the successful application for funding for a comprehensive AMR surveillance project. The project was developed by investigators from Botswana-UPenn Partnership (BUP) in collaboration with Botswana's Ministry of Health & Wellness (MOHW) and the University of Botswana (UB). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04182230 -
UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections
|
||
| Recruiting |
NCT02814877 -
Efficacy and Cost-effectiveness of Hospital Antimicrobial Stewardship Programs
|
N/A | |
| Completed |
NCT03388944 -
PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis
|
N/A | |
| Completed |
NCT03794479 -
Intestinal Microbiota and Antimicrobial Resistance in Hong Kong Residents After Travel
|
||
| Recruiting |
NCT05942157 -
Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections
|
N/A | |
| Recruiting |
NCT05296837 -
Ocular Rosacea Biome Study
|
Phase 4 | |
| Completed |
NCT05451836 -
N-of-1 Trials of Interventions to Improve Decision-making for Antibiotic Use
|
N/A | |
| Not yet recruiting |
NCT05960084 -
Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia
|
||
| Completed |
NCT05445414 -
A Mobile App Serious Game to Increase Awareness of Antibiotic Use in the Community
|
N/A | |
| Not yet recruiting |
NCT05089760 -
Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China
|
||
| Recruiting |
NCT04388293 -
Using Antibiotics Wisely - An Antimicrobial Stewardship Program
|
||
| Recruiting |
NCT05285657 -
Algorithm Using a Rapid Diagnostic Test for the Management of Childhood Febrile Diseases.
|
N/A | |
| Completed |
NCT03479710 -
Fecal Microbiota Transplantation for CRE/VRE
|
Phase 2 | |
| Not yet recruiting |
NCT06358872 -
Azithromycin for Child Survival in Niger II
|
Phase 4 | |
| Not yet recruiting |
NCT06305455 -
Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
|
||
| Not yet recruiting |
NCT06356285 -
Testing New Ways to Name Antimicrobial Resistance
|
N/A |